Notice Number: NOT-HL-19-691
Key Dates
Release Date: April 12, 2019
Issued by
National Heart, Lung, and Blood Institute (NHLBI)
Purpose
On March 11, 2019, NHLBI issued RFA-HL-20-009, "BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia and hemorrhagic conditions in low or lower-middle income countries (LLMICs) in Sub-Saharan Africa (UG3/UH3 Clinical Trial Optional)". The purpose of this Notice is to change the key dates and to clarify the Eligibility Information.
Key Dates
Application Due Date(s)
Current Language:
May 20, 2019, by 5:00 PM local time of applicant organization.
Revised Language:
June 11, 2019, by 5:00 PM local time of applicant organization.
Scientific Merit Review
Current Language:
November 2019
Revised Language:
December 2019
Expiration Date
Current Language:
May 21, 2019
Revised Language
June 12, 2019
Section III. Eligibility Information
1. Eligible Applicants
Eligible Individuals (Program Director/Principal Investigator)
Current Language:
The primary PD/PI must have a academic appointment at an institution in a low income or lower-middle income country (by the World Bank criteria) in Sub-Saharan Africa. This academic affiliation must constitute at least 50% of the PD/PI full time professional effort in the past 2 years.
Revised Language:
The primary PD/PI should have an appointment at an institution in a low income or lower-middle income country (by the World Bank criteria) in Sub-Saharan Africa. This affiliation should constitute at least 50% of the PD/PI full time professional effort in the past 2 years.
All other aspects of this FOA remain unchanged.
This Notice is also to inform potential applicants that NHLBI has posted a set of responses to Frequently Asked Questions (FAQs) regarding RFA-HL-20-009. The FAQs are available on the NHLBI website at the following link: https://www.nhlbi.nih.gov/node-general/frequently-asked-questions-bloodsafe-research-enhance-availability-safe-blood-patients, which may be updated when additional questions are asked.
Inquiries
Please direct all inquiries to:
Shimian Zou, PhD
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0065
Email: shimian.zou@nih.gov
LeShawndra Price, PhD
Center for Translation Research and Implementation Science
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8166
Email: leshawndra.price@nih.gov
and Human Services (HHS)
